Synolo Therapeutics is advancing a new class of therapeutics for cancer. Launched by RA Ventures* and leveraging a proprietary discovery platform, we are rapidly building a pipeline of differentiated conditionally-active immunotherapies which promise to be highly effective and safer than the current standard of care.
*RA Ventures is the venture focused division of RA Capital Management.
Company Details
- Employees
- 15
- Founded
- 2023
- Address
- Cambridge, Massachusetts 02139, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.synolotx.com
- Keywords
- Boston.
- HQ
- Cambridge, Massachusetts
Synolo Therapeutics Questions
Synolo Therapeutics's website is http://www.synolotx.com
Synolo Therapeutics's LinkedIn profile is https://www.linkedin.com/company/synolotherapeutics
Synolo Therapeutics has
15 employees.
View email and phone details for 15
employees at Synolo Therapeutics.
Synolo Therapeutics's industry is
Biotechnology Research
Synolo Therapeutics's top competitors are
Cue Biopharma,
Kano Therapeutics,
Ra Capital Management,
Grik Therapeutics,
Tessera Therapeutics,
Raven (Ra Ventures),
Tasca Therapeutics,
Epivax, Inc.,
Hifibio Therapeutics,
Skyhook.
Synolo Therapeutics's categories are Biotechnology Research
Synolo Therapeutics's founding year is 2023
